Orally administered pharmaceutical dosage form for 2 group inhibitors of BCL

Orally administered pharmaceutical dosage form for 2 group inhibitors of BCL

  • CN 106,074,391 A
  • Filed: 06/08/2010
  • Published: 11/09/2016
  • Est. Priority Date: 06/08/2009
  • Status: Active Application
First Claim
Patent Images

1. a pharmaceutical dosage form, it comprises:

  • N-(4-(4-((2-(4-chlorphenyl)-5,5-dimethyl-1-hexamethylene-1-alkene-1-base) methyl) piperazine-1-base) benzoylBase)-4-(((1R)-3-(morpholine-4-base)-1-((Phenylsulfanyl) methyl) propyl group) amino)-3-((trifluoromethyl) sulphonylBase) benzsulfamide, its salt or its hydrate,Comprise the copolymer of N-vinylpyrrolidone at least one pharmaceutically acceptable polymer,Selected from having the tocopherol compound of polyalkylene glycol moiety, sorbitan fatty acid esters, polyoxyethylene mountainSingle pharmaceutically acceptable solubilizing agent in pears sugar alcohol fatty acid ester and alkyl sulfate andPropylene glycol,Wherein said N-(4-(4-((2-(4-chlorphenyl)-5,5-dimethyl-1-hexamethylene-1-alkene-1-base) methyl) piperazine-1-Base) benzoyl)-4-(((1R)-3-(morpholine-4-base)-1-((Phenylsulfanyl) methyl) propyl group) amino)-3-((fluoroformBase) sulfonyl) benzsulfamide, its salt or its hydrate be dispersed in solid dispersion with the concentration of 0.5-40% by weightIn product, this solid dispersion product comprises 40-97.5% by weight above-mentioned further, and at least one is pharmaceutically acceptableThe above-mentioned single pharmaceutically acceptable solubilizing agent of polymer, by weight 2-20% and above-mentioned propylene glycol.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×